Are Sickle Cell Pain Trials Asking the Wrong Question? STArT Investigator Examines Current End Points
In an interview with Pharmacy Times, Claudia R. Morris, MD, lead author of the phase 3 STArT trial and professor of pediatrics and emergency medicine at Emory University School of Medicine, discusses findings from the phase 3 STArT trial of intravenous arginine for acute sickle cell pain, limitations of time to crisis resolution as a clinical trial end point, and opportunities for pharmacists to improve opioid-use data collection.
In an interview with Pharmacy Times, Claudia R. Morris, MD, lead author of the phase 3 STArT trial and professor of pediatrics and emergency medicine at Emory University School of Medicine, discussed why intravenous arginine did not improve time to crisis resolution, how institutional practices and differences in patients’ pain can affect trial results, and why researchers need better ways to measure treatment success in acute sickle cell pain.